Quick Sepsis Test

Project Information

QUIST

Grant agreement ID: 663039

DOI 10.3030/663039

Project closed

EC signature date 23 December 2014

Start date 1 January 2015

End date 30 June 2015

Funded under

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Total cost € 71 429,00

EU contribution € 50 000,00

Coordinated by

ABUNDNZ BV
Netherlands

Objective

In QUIST, a protein will be validated as a biomarker for early detection and prognosis of sepsis in combination with several other surrogate sepsis biomarkers. Specific objective is:
• To perform a feasibility study in order to gain better insight in the risks and potential hurdles for the validation study in Phase 2 and future exploitation of the project’s results. This study will contain technical, commercial and economical issues.

Expected outcomes:
• A solid businessplan as a result of the feasibility study. This businessplan will contain information that is currently incomplete or lacking about the market (identification of potential customers, competitors, distributors and competing technologies), regulations and industrial partners for the commercial development of a POCT for sepsis. Based on this information, also a strategy will be defined for IP management.
• A research plan for the validation study, addressing technical hurdles defined in the feasibility study.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.

• social sciences › sociology › demography › mortality
• medical and health sciences › health sciences › infectious diseases
• medical and health sciences › basic medicine › immunology
• medical and health sciences › basic medicine › pharmacology and pharmacy › pharmaceutical drugs › antibiotics
• natural sciences › chemical sciences › analytical chemistry › mass spectrometry

You need to log in or register to use this function

Programme(s)

• H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme
• H2020-EU.3.1.3. - Treating and managing disease

Topic(s)

• PHC-12-2014-1 - Clinical research for the validation of biomarkers and/or diagnostic medical devices

Call for proposal

H2020-SMEInst-2014-2015

See other projects for this call

Sub call

H2020-SMEINST-1-2014

Funding Scheme

SME-1 - SME instrument phase 1

Coordinator

ABUNDNZ BV

• Net EU contribution: € 50 000,00
• Address: BRUSSELLAAN 7 ; 3446 AL WOERDEN ; Netherlands
• SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes:
  Region
  West-Nederland › Utrecht › Utrecht
• Region: West-Nederland › Utrecht › Utrecht
• Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Total cost: € 71 429,00